Aethlon Medical Approves Reverse Stock Split Plan

Aethlon Medical ( (AEMD) ) has provided an update.

Aethlon Medical, Inc. held a Special Meeting of Stockholders on May 13, 2025, where a reverse stock split of the company’s common stock was approved. The reverse stock split, at a ratio of 1-for-8, will be implemented on June 6, 2025, with trading on a split-adjusted basis commencing on June 9, 2025. This action will proportionately adjust the per share exercise price and the number of shares issuable upon the exercise or vesting of stock options, restricted stock units, and warrants, while ensuring no fractional shares are issued. The move is designed to consolidate shares and adjust equity compensation plans, impacting all stockholders proportionately without altering their percentage ownership in the company.

The most recent analyst rating on (AEMD) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Aethlon Medical stock, see the AEMD Stock Forecast page.

Spark’s Take on AEMD Stock

According to Spark, TipRanks’ AI Analyst, AEMD is a Underperform.

Aethlon Medical’s overall stock score is low due to significant financial challenges, including persistent losses and cash flow issues. The technical indicators suggest negative momentum, and the valuation is unattractive given the negative P/E ratio and lack of dividends. While the earnings call presented some positive strategic efforts, such as cost reduction and trial advancements, the hurdles in clinical trials and financial constraints weigh heavily on the stock’s outlook.

To see Spark’s full report on AEMD stock, click here.

More about Aethlon Medical

Average Trading Volume: 131,616

Technical Sentiment Signal: Strong Sell

Current Market Cap: $5.63M

For a thorough assessment of AEMD stock, go to TipRanks’ Stock Analysis page.